FOR IMMEDIATE RELEASE:
CANNABIS/BUSINESS/EVENT/WOMEN IN BUSINESS
ITEM 9 LABS CORP. CEO SARA GULLICKSON
TO DISCUSS CANNABIS LAWS & REGULATIONS AT
XLIVE CONFERENCE IN LAS VEGAS
SCOTTSDALE, Ariz., December 7, 2018 (GLOBE NEWSWIRE) – Sara Gullickson, CEO of Item 9 Labs Corp. (OTC: INLB), announced she will speak at the 2018 XLive Conference as part of the Cannabis Lab spotlight program, December 9-12, at the Mandalay Bay Resort and Casino, 3950 Las Vegas Blvd. S., in Las Vegas, Nevada.
New this year, the Cannabis Lab is a four-hour session devoted to cannabis culture in the live event space, with a focus on recreational markets. Gullickson will discuss, “Budding Legalities: Understanding Cannabis Laws and Regulations,” from 2:40 – 3:40 p.m., on Sunday, December 9.
Cannabis Lab presentations will also cover how to work with cannabis vendors, producing cannabis-centered events, building cannabis activations, and how to incorporate cannabis into a live event.
An award-winning international cannabis consultant and industry spokesperson, Gullickson has licensing success in over a dozen markets and has helped shape marijuana programs in the United States, Canada, Europe, and New Zealand.
Gullickson was recently named CEO of publicly traded Item 9 Labs Corp., a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms. She is also the owner of Strive Wellness of Nevada LLC, a medical cannabis cultivation and processing facility with distribution rights.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.: Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of todays modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.